JP Stock MarketDetailed Quotes

4503 Astellas Pharma

Watchlist
  • 1734.5
  • 0.00.00%
20min DelayMarket to Open Nov 7 15:30 JST
3.14TMarket Cap183.16P/E (Static)

Astellas Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Astellas Pharma H1 FY2025 Earnings Date

Currency：JPYOct 30, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
916.18B
935.62B
+19.44B
Beat Est.
+19.43%
+21.96%
+4.57%
EPS
--
40.91
--
+105.58%
Analyst Rating
Buy

Nov 4, 2024

Astellas Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 421.390B--
--2025/Q3-- / 451.075B--
Oct 30, 20242025/Q2462.497B / 425.282B--
Aug 1, 20242025/Q1473.124B / 411.415B--
Apr 25, 20242024/Q4414.602B / 381.093B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 421.390B--
--2025/Q3-- / 451.075B--
Oct 30, 20242025/Q2462.497B / 425.282B--
Aug 1, 20242025/Q1473.124B / 411.415B--
Apr 25, 20242024/Q4414.602B / 381.093B--

Unlock Free Earnings Estimates

Astellas Pharma Earnings Reports

  • Astellas Pharma: Confirmation letter

    Nov 5 23:52 ET

  • Astellas Pharma: Half Year Report - Term 20 (2024/04/01 - 2025/03/31)

    Nov 5 23:51 ET

  • Astellas Pharma: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

    Oct 30 02:00 ET

  • Astellas Pharma: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

    Oct 30 02:00 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 4, 2024

    Buy

    • Strong Buy

      40.00%

    • Buy

      13.33%

    • Hold

      40.00%

    • Underperform

      6.67%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg

    No Data